Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Trial ID or NCT#
NCT00398372
Status
NOT RECRUITING
Purpose
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Official Title
Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Wen-Kai Weng, MD, PhD
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Lymphoma specialist,
Medical oncologist,
Multiple myeloma specialist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Ronald Levy, MD
Medical oncologist,
Lymphoma specialist
Robert K. and Helen K. Summy Professor in the School of Medicine
Contact us to find out if this trial is right for you.
Contact
Mayita Romero
6507256452
View on ClinicalTrials.gov
